Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted) (2009 - 2026)
Biomarin Pharmaceutical (BMRN) recorded quarterly EPS (Weighted Average and Diluted) of $0.54 in Q1 2026, up 325.0% on a QoQ basis from -$0.24 in Q4 2025, and down 43.16% year-over-year from $0.95 in Q1 2025.
Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted) (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical has disclosed EPS (Weighted Average and Diluted) across 18 years of filings, most recently posting $0.54 for Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 43.16% year-over-year to $0.54 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.37 (down 49.26% YoY) and the FY2025 annual result came in at $1.8, down 18.55% from the prior year.
- EPS (Weighted Average and Diluted) rose to $0.54 in Q1 2026, from -$0.24 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $1.23 in Q2 2025 and troughed at -$0.24 in Q4 2025.
- A 5-year average of $0.36 and a median of $0.29 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) soared 7688.88% — and 2025, when it slumped 136.92%.
- Tracing BMRN's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.0 in 2022, then surged by 7688.88% to $0.1 in 2023, then jumped by 550.0% to $0.65 in 2024, then sank by 136.92% to -$0.24 in 2025, then jumped by 325.0% to $0.54 in 2026.
- Business Quant data shows BMRN's EPS (Weighted Average and Diluted) at $0.54 in Q1 2026, -$0.24 in Q4 2025, and -$0.16 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Biomarin Pharmaceutical | 10.52 Bn | 8.29 Bn | 571.21 Mn | 0.54 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.54 |
| Dec 31, 2025 | -0.24 |
| Sep 30, 2025 | -0.16 |
| Jun 30, 2025 | 1.23 |
| Mar 31, 2025 | 0.95 |
| Dec 31, 2024 | 0.65 |
| Sep 30, 2024 | 0.55 |
| Jun 30, 2024 | 0.55 |
| Mar 31, 2024 | 0.46 |
| Dec 31, 2023 | 0.10 |
| Sep 30, 2023 | 0.21 |
| Jun 30, 2023 | 0.29 |
| Mar 31, 2023 | 0.27 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | -0.04 |
| Jun 30, 2022 | 0.15 |
| Mar 31, 2022 | 0.63 |
| Dec 31, 2021 | -0.32 |
| Sep 30, 2021 | -0.20 |
| Jun 30, 2021 | 0.07 |